The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in first-in-human phase I study: The START Center experience.
T. Shimizu
No relevant relationships to disclose
A. W. Tolcher
No relevant relationships to disclose
K. P. Papadopoulos
No relevant relationships to disclose
M. Beeram
No relevant relationships to disclose
D. W. Rasco
No relevant relationships to disclose
L. S. Smith
No relevant relationships to disclose
S. Gunn
No relevant relationships to disclose
L. Smetzer
No relevant relationships to disclose
T. A. Mays
No relevant relationships to disclose
B. Kaiser
No relevant relationships to disclose
C. Alvarez
No relevant relationships to disclose
G. L. Mangold
No relevant relationships to disclose
A. Patnaik
No relevant relationships to disclose